ATR APTARGROUP, INC.
Price Chart
Executive Summary
AptarGroup reported Q1 2026 GAAP diluted EPS of $1.12, down 4% YoY from $1.17, and adjusted EPS of $1.19, down 8% YoY at constant currency. Reported sales rose 11% to $982.9M, but core sales were flat, and adjusted EBITDA margin contracted 150 bps to 19.2%. The company guided Q2 2026 adjusted EPS to $1.32-$1.40, below the $1.67 reported in Q2 2025, signaling continued margin pressure from emergency medicine destocking and operational disruptions.
Key Financial Metrics
Actionable Insight
The flat core sales and declining margins confirm the emergency medicine headwind is persisting longer than anticipated. Q2 guidance implies a significant sequential improvement but still well below prior year — watch for execution on the injectables GLP-1 ramp and any further destocking commentary on the earnings call. The CEO transition adds medium-term uncertainty.
Key Facts
- GAAP diluted EPS of $1.12 vs $1.17 YoY, a 4% decline
- Adjusted EPS of $1.19 vs $1.30 YoY at constant currency, down 8%
- Reported sales +11% to $982.9M, but core sales flat (0%)
- Adjusted EBITDA margin 19.2% vs 20.7% YoY, down 150 bps
- Pharma core sales declined 1%; emergency medicine destocking continued
- Beauty core sales +3%; Closures core sales flat
- Q2 2026 adjusted EPS guidance $1.32-$1.40, well below Q2 2025's $1.67
- Operating cash flow improved to $118.7M from $82.7M YoY
- Returned $131M to shareholders via buybacks and dividends
- Gael Touya named next CEO effective September 1, 2026
Financial Impact
GAAP EPS declined $0.05 YoY; adjusted EPS declined $0.11 YoY; Q2 guidance midpoint $1.36 is 18.6% below prior year's $1.67
Risk Factors
- Emergency medicine destocking may persist beyond Q2, pressuring Pharma segment
- Q2 guidance midpoint $1.36 is 18.6% below Q2 2025 actual of $1.67, implying continued earnings contraction
- Margin compression across all three segments (Pharma -150bps, Beauty -100bps, Closures -270bps)
- CEO transition effective September 2026 introduces leadership uncertainty
- Ongoing litigation costs (ARS Pharmaceuticals, Nemera) excluded from adjusted metrics but represent real cash outflow
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000896622-26-000090 |
| Document: atr-20260430.htm | 0000896622-26-000090 |
| Document: 0000896622-26-000090-index-headers.html | 0000896622-26-000090 |
| Document: 0000896622-26-000090-index.html | 0000896622-26-000090 |
| Document: 0000896622-26-000090.txt | 0000896622-26-000090 |
| 8-K Data (Synthetic) | 0000896622-26-000090 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 30, 2026
5w ago
|
8-K
| $118.55 $112.38 | ▲ +5.21% | ▲ +10.47% | $115.90 (+2.24%) |
|
Mar 27, 2026
10w ago
|
DEFA14A
| $121.51 $124.73 | ▲ +2.65% | ▼ −10.09% | $115.90 (−4.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access